Journal Club VL

Practical Considerations For the Use of Switch Maintenance Therapy: Avelumab First-Line Maintenance in Locally Advanced or Metastatic Urothelial Carcinoma Journal Club - Christopher Wallis & Zachary K...

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen provide insights into the Cancer Treatment Reviews publication Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. In the context of metastatic urothelial carcinoma, avelumab has previously been assessed in a large phase 1b study, using a...

Metastasis-Directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen provide insights into the European Urology publication titled " Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis " in this UroToday Journal Club. The question that the authors sought to assess is if data could be derived assessing whether...

The Decipher® Genomic Classifier for Recurrent Prostate Cancer in the NRG/RTOG 9601 Randomized Clinical Trial, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen provide insights into the JAMA Oncology publication titled Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. The management of patients with localized and recurrent prostate cancer is driven predominantly at this point by cli...

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma a UroToday Journal Club - Christopher Wallis and Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen provide insights into the NEJM publication titled Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma from the EV-301 trial. Zachary and Chris discuss the background on enfortumab vedotin, the trial design, methods, results, and conclusions. In light of recent data supporting maintenance treatment with avelum...

Survivorship Care Plans Addressing Long-term Mental Health Among Survivors of Testicular Cancer, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Testicular cancer survivors may experience mental illness as a consequence of their cancer diagnosis and treatment. A recently published article titled, "Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study" focuses on survivorship care plans for testicular cancer patients. In this UroToday Journal Club, Christopher Wallis, MD, Ph.D., an...

Real-World Treatment Patterns and Health Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) - Christopher Wallis and Zachary Klaassen

Details
In this Journal Club video presentation, Christopher Wallis, MD, PhD, and Zachary Klaassen, MD describe a Clinical Genitourinary Cancer publication Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. The primary objective of this analysis is to describe real-world treatment patterns, includ...

Stereotactic Ablative Body Radiotherapy in Patients in Oligometastatic Cancers: A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the recently published article in the Lancet Oncology, "Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: A prospective, registry-based, single-arm, observational, evaluation study." Patients with oligometastatic disease have a more favorable prognosis than those with widespread metastati...

Racial Disparity and Outcomes Among US Patients with Cancer and COVID-19 A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss an analysis of risk, racial disparity, and outcomes among United States patients with cancer and COVID-19 infections. In this case-control study, patients with cancer were at significantly increased risk for COVID-19 infection, which was further exacerbated among African Americans, highlighting the need to protect and m...

Durvalumab Vs. Chemotherapy in Previously Untreated Patients with Unresectable Metastatic Urothelial Carcinoma (DANUBE) A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this Journal Club, Christopher Wallis and Zachary Klaassen review the September 2020 publication The Lancet Oncology: Durvalumab Alone and Durvalumab plus Tremelimumab Versus Chemotherapy in Previously Untreated Patients with Unresectable, Locally Advanced or Metastatic Urothelial Carcinoma (DANUBE): A Randomised, Open-Label, Multicentre, Phase 3 Trial. DANUBE was conducted at 224 academic rese...

Extended 4-Year Followup of CheckMate 214 Trial, Nivolumab Plus Ipilimumab for First-Line Treatment of Advanced Renal Cell Carcinoma: A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
After long-term follow-up, Nivolumab Plus Ipilimumab continues to demonstrate durable efficacy benefits vs sunitinib, with manageable safety. Nivolumab plus ipilimumab (NIVO+IPI) combination immunotherapy was the first to demonstrate superiority over sunitinib (SUN) in the first-line treatment of patients with advanced renal cell carcinoma (aRCC). NIVO+IPI is currently approved for clinical use in...